SOME LESSONS FROM EUROPEAN INTEGRATION OF UKRAINE

The article is devoted to how the events of 2022 and early 2023. influenced the process of integration of Ukraine economic and political space of the European Union. She would hardly have survived without the assistance of the EU member states. For it, the question of the forms, pace and timing of European integration for Kyiv has evolved from much theoretical to practical and urgent. The speed of its restoration will also depend on the answer to this question, and the future of the EU, its «strategic autonomy» will depend on how and when the armed conflict and political crisis in Eastern Europe will end. How everything that has happened to Ukraine during this time has affected the process of its integration with the EU is difficult to assess unequivocally. On the one hand, one of its main conditions - achieving a level of development comparable to other EU countries, economic and political-legal compatibility, geopolitical risks have increased as well. The armed conflict has exacerbated the ongoing difficulties of transformation. On the other hand, doubts about the viability of the Ukrainian state, the stability of its foreign policy orientation have eased, mutual rapprochement has accelerated at the economic, political and (due to mass emigration to EU member states) even at the personal levels. There is an obvious need to rethink and clarify the objectives of the relevant policy, the possibilities, ways and timing of their achievement

Effect of the Etching Profile of a Si Substrate on the Capacitive Characteristics of Three-Dimensional Solid-State Lithium-Ion Batteries

Along with the soaring demands for all-solid-state thin-film lithium-ion batteries, the problem of their energy density rise becomes very acute. The solution to this problem can be found in development of 3D batteries. The present work deals with the development of a technology for a 3D solid-state lithium-ion battery (3D SSLIB) manufacturing by plasma-chemical etching and magnetron sputtering technique. The results on testing of experimental samples of 3D SSLIB are presented. It was found that submicron-scale steps appearing on the surface of a 3D structure formed on Si substrate by the Bosch process radically change the crystal structure of the upper functional layers. Such changes can lead to disruption of the layers’ continuity, especially that of the down conductors. It is shown that surface polishing by liquid etching of the SiO2 layer and silicon reoxidation leads to surface smoothing, the replacement of the dendrite structure of functional layers by a block structure, and a significant improvement in the capacitive characteristics of the battery

Effect of the Etching Profile of a Si Substrate on the Capacitive Characteristics of Three-Dimensional Solid-State Lithium-Ion Batteries

Along with the soaring demands for all-solid-state thin-film lithium-ion batteries, the problem of their energy density rise becomes very acute. The solution to this problem can be found in development of 3D batteries. The present work deals with the development of a technology for a 3D solid-state lithium-ion battery (3D SSLIB) manufacturing by plasma-chemical etching and magnetron sputtering technique. The results on testing of experimental samples of 3D SSLIB are presented. It was found that submicron-scale steps appearing on the surface of a 3D structure formed on Si substrate by the Bosch process radically change the crystal structure of the upper functional layers. Such changes can lead to disruption of the layers’ continuity, especially that of the down conductors. It is shown that surface polishing by liquid etching of the SiO2 layer and silicon reoxidation leads to surface smoothing, the replacement of the dendrite structure of functional layers by a block structure, and a significant improvement in the capacitive characteristics of the battery

Determination of Diffusion Coefficients of Lithium in Solid Electrolyte LiPON

A structural model of LiPON solid electrolyte, containing elements that simulate drift conductivity, diffusion conductivity, and leakage current was proposed. The dependence of the impedance of the structural model on frequency was calculated, and the parameters of the model at which the theoretical curve best approximates the experimental Nyquist diagrams were determined. Based on these data, the ion diffusion coefficient and conductivity of LiPON were calculated, which are D1 = 1.5 × 10−11 cm2/s and σ = 1.9 × 10−6 S/cm, respectively

Corridor Redesign of Chancellor Boulevard

MTT Consulting has been tasked with redesigning Chancellor Boulevard between Acadia Road and Drummond Drive. The existing corridor has been assessed and significant issues noted, including: deteriorating road surfaces, a lack of defined bike lanes, vehicles speeding, and traffic congestion near Hamber Road. The preferred design promotes safety and active transportation on the corridor which are in line with the community and client’s goals. The finalized design is defined by the following aspects: ● Multi-modal transportation infrastructure: a two-way bike path and wide pedestrian path on the south side and a multi-use pathway on the north side, ● Four lanes are maintained for vehicle traffic: The roadway has been developed to lower driving speeds including narrowing the lanes and median. ● Pedestrian underpass: Located at Hamber Road near the bus stops and Hamber Elementary School to accommodate the high pedestrian traffic at that intersection and allow for the removal of the existing signal light. The underpass was analyzed and designed in accordance to CSA standards. Synchro analysis software was used for the intersection design, concluding that the intersection of Chancellor Boulevard and Hamber Road will be reconfigured to a protected-T intersection from the existing pedestrian-controlled half signal. Corridor traffic analysis and design was completed in accordance with the Highway Capacity Manual and TAC and AASHTO Standards . Construction is scheduled for May, 2018 with expected completion in August 2018. Based on a Class A cost estimate, the expected total cost for the project will be $4.75 million with an annual maintenance cost of$48,000, including the repair and remediation and preventative maintenance costs. Disclaimer: “UBC SEEDS provides students with the opportunity to share the findings of their studies, as well as their opinions, conclusions and recommendations with the UBC community. The reader should bear in mind that this is a student project/report and is not an official document of UBC. Furthermore readers should bear in mind that these reports may not reflect the current status of activities at UBC. We urge you to contact the research persons mentioned in a report or the SEEDS Coordinator about the current status of the subject matter of a project/report.”Applied Science, Faculty ofCivil Engineering, Department ofUnreviewedUndergraduat

RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial.

Peer reviewed: TrueAcknowledgements: The authors thank Stefano Elli, Federico Sala, Cesare Cosentino, and Marco Guerrini for the docking and molecular dynamic simulations and for contributions to structural analysis and in silico analyses reported elsewhere, which were invaluable for the design of this study. In addition, the authors would like to thank Alexander Walker, Haitian Fan, Jeremy Keown, Denisa Bojkova, Marco Bechtel, Xinjian Peng, Jindrich Cinatl, Jonathan Grimes, and Ervin Fodor for contributions to in vitro experiments reported elsewhere, which were invaluable for making this study possible. The authors would also like to thank Bill Johnson, Miguel Muzzio, and David Boltz for valuable results and discussions regarding toxicology studies performed at their facility, as well as Juergen Richt for helpful discussions regarding the antiviral efficacy of the test compound.Publication status: PublishedEnisamium is an orally available therapeutic that inhibits influenza A virus and SARS-CoV-2 replication. We evaluated the clinical efficacy of enisamium treatment combined with standard care in adult, hospitalized patients with moderate COVID-19 requiring external oxygen. Hospitalized patients with laboratory-confirmed SARS-CoV-2 infection were randomly assigned to receive either enisamium (500 mg per dose, four times a day) or a placebo. The primary outcome was an improvement of at least two points on an eight-point severity rating (SR) scale within 29 days of randomization. We initially set out to study the effect of enisamium on patients with a baseline SR of 4 or 5. However, because the study was started early in the COVID-19 pandemic, and COVID-19 had been insufficiently studied at the start of our study, an interim analysis was performed alongside a conditional power analysis in order to ensure patient safety and assess whether the treatment was likely to be beneficial for one or both groups. Following this analysis, a beneficial effect was observed for patients with an SR of 4 only, i.e., patients with moderate COVID-19 requiring supplementary oxygen. The study was continued for these COVID-19 patients. Overall, a total of 592 patients were enrolled and randomized between May 2020 and March 2021. Patients with a baseline SR of 4 were divided into two groups: 142 (49.8%) were assigned to the enisamium group and 143 (50.2%) to the placebo group. An analysis of the population showed that if patients were treated within 4 days of the onset of COVID-19 symptoms (n = 33), the median time to improvement was 8 days for the enisamium group and 13 days for the placebo group (p = 0.005). For patients treated within 10 days of the onset of COVID-19 symptoms (n = 154), the median time to improvement was 10 days for the enisamium group and 12 days for the placebo group (p = 0.002). Our findings suggest that enisamium is safe to use with COVID-19 patients, and that the observed clinical benefit of enisamium is worth reporting and studying in detail

RNA Polymerase Inhibitor Enisamium for Treatment of Moderate COVID-19 Patients: A Randomized, Placebo-Controlled, Multicenter, Double-Blind Phase 3 Clinical Trial

Enisamium is an orally available therapeutic that inhibits influenza A virus and SARS-CoV-2 replication. We evaluated the clinical efficacy of enisamium treatment combined with standard care in adult, hospitalized patients with moderate COVID-19 requiring external oxygen. Hospitalized patients with laboratory-confirmed SARS-CoV-2 infection were randomly assigned to receive either enisamium (500 mg per dose, four times a day) or a placebo. The primary outcome was an improvement of at least two points on an eight-point severity rating (SR) scale within 29 days of randomization. We initially set out to study the effect of enisamium on patients with a baseline SR of 4 or 5. However, because the study was started early in the COVID-19 pandemic, and COVID-19 had been insufficiently studied at the start of our study, an interim analysis was performed alongside a conditional power analysis in order to ensure patient safety and assess whether the treatment was likely to be beneficial for one or both groups. Following this analysis, a beneficial effect was observed for patients with an SR of 4 only, i.e., patients with moderate COVID-19 requiring supplementary oxygen. The study was continued for these COVID-19 patients. Overall, a total of 592 patients were enrolled and randomized between May 2020 and March 2021. Patients with a baseline SR of 4 were divided into two groups: 142 (49.8%) were assigned to the enisamium group and 143 (50.2%) to the placebo group. An analysis of the population showed that if patients were treated within 4 days of the onset of COVID-19 symptoms (n = 33), the median time to improvement was 8 days for the enisamium group and 13 days for the placebo group (p = 0.005). For patients treated within 10 days of the onset of COVID-19 symptoms (n = 154), the median time to improvement was 10 days for the enisamium group and 12 days for the placebo group (p = 0.002). Our findings suggest that enisamium is safe to use with COVID-19 patients, and that the observed clinical benefit of enisamium is worth reporting and studying in detail